Workflow
Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit
OppenheimerOppenheimer(US:OPY) GlobeNewswire News Roomยท2024-06-17 20:30

Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for treating chronic mast and stem cell diseases [2][5] - The company aims to address conditions such as chronic urticaria and myelodysplastic syndromes (MDS), as well as serve as a conditioning agent for stem cell transplants in rare diseases like sickle cell disease, Fanconi anemia, and severe combined immunodeficiency [2][5] Clinical Development - Briquilimab has shown efficacy and safety in over 145 participants, including healthy volunteers, with positive clinical outcomes in conditions such as SCID, acute myeloid leukemia, MDS, FA, and SCD [2] - The company will present its findings at the Oppenheimer Novel Targets in Immunology Summit on June 24, 2024, in New York City [5] Market Focus - Jasper Therapeutics is targeting mast cell-driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma, indicating a focused approach in the immunology sector [5]